> ## Content Index
> Fetch the complete content index at: https://nephspace.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Weekly · Nov 16: How Low to Go on Blood Pressure, People Over Pop-ups, the Fistula and the Heart, and the Silent Brain
- URL: https://nephspace.com/weekly-nov-16/
- Published: 2026-11-16T12:01:27.000Z
- Updated: 2026-11-16T12:01:27.000Z
- Description: Your weekly digest: one blood pressure target, two trials, two answers; what actually gets CKD treated; and the strokes nobody sees.
- Author: Dr Wael Hussein
- Tags: Episodes, Hypertension, CKD and cardiometabolic, Dialysis, #weekly, #has-audio, #tr-be7fb7bc

This week is all about pressure. Two new trials from Brazil tested a systolic target under 120, one in type 2 diabetes and one after a stroke: one group came out ahead, and in both, the kidneys had something to say. A trial in Colombia and Jamaica where one combination pill and a team got blood pressure under control, and a review of two dozen studies on what actually gets CKD tested and treated. Heart-related hospital stays after a fistula or graft is made: four in ten Medicare patients within a year, though most already had heart disease. And the silent strokes that show up on brain scans in kidney disease.

**Disclosure:** No spoken disclosure this week; nothing in this episode touches a dialysis product or a payment rule. OPTIMAL trials: funded by Hospital Israelita Albert Einstein and the Brazilian Ministry of Health (PROADI-SUS); Servier donated the drugs (no role, per OPTIMAL-DIABETES). CATCH: funded by NHLBI; one author reports personal fees from Omega Research Group, one reports ties to Dr. Reddy's Laboratories Jamaica and Aventa Jamaica, and one speaker fees from Carimed. JASN review: funded by the Duke Clinical Research Institute; several authors report industry consultancy. Kidney360 cohort: one author consults for Humacyte, Venova and LeMaitre and reports research funding from access-device companies. AJKD review: no support and no relevant financial interests.

## Chapters

- **01:47** How low, and for whom · [Read the story](https://nephspace.com/optimal-trials-blood-pressure-target-diabetes-stroke/)
- **09:27** People, not pop-ups · Read the stories: [1](https://nephspace.com/catch-trial-single-pill-team-care/), [2](https://nephspace.com/ckd-testing-treatment-alerts-vs-people/)
- **15:37** The fistula and the heart · [Read the story](https://nephspace.com/heart-hospitalizations-after-av-access-medicare/)
- **18:50** The silent brain · [Read the story](https://nephspace.com/silent-cerebrovascular-disease-ckd/)

## Papers in this episode

- Santo K, Martins E, et al. OPTIMAL-DIABETES: intensive versus standard systolic blood pressure targets in type 2 diabetes. N Engl J Med. Published online November 7, 2026\. [Link](https://doi.org/10.1056/NEJMoa2612922?ref=nephspace.com)
- OPTIMAL-STROKE: intensive versus standard systolic blood pressure targets after ischemic stroke or transient ischemic attack. N Engl J Med. Published online November 7, 2026\. [Link](https://doi.org/10.1056/NEJMoa2612924?ref=nephspace.com)
- Lopez-Lopez JP, Duncan J, Chen J, et al. Implementation of Single-Pill Combination Therapy Through Team-Based Care for Hypertension Control in Resource-Constrained Settings. JAMA. Published online November 8, 2026\. [Link](https://doi.org/10.1001/jama.2026.24169?ref=nephspace.com)
- Edmonston D, et al. Implementation Strategies to Improve CKD Testing and Delivery of Guideline-Directed Medical Therapy: A Scoping Review. J Am Soc Nephrol. Published online November 12, 2026\. [Link](https://doi.org/10.1681/ASN.0000001324?ref=nephspace.com)
- Smith H, et al. Cardiac Complications following Creation of Arteriovenous Access in Medicare Beneficiaries with ESKD. Kidney360\. Published online November 10, 2026\. [Link](https://doi.org/10.34067/KID.0000001419?ref=nephspace.com)
- Vasaghi-Gharamaleki M, et al. The Burden of Occult Cerebrovascular Disease in CKD: A Scoping Review. Am J Kidney Dis. Published online November 10, 2026\. [Link](https://doi.org/10.1053/j.ajkd.2026.07.018?ref=nephspace.com)

## Also on the website this week (not in the episode)

- Pinto LCS, et al. Beyond Access Flow: The FLASH Multiorgan Framework for Assessing High-Flow Arteriovenous Fistulas in Hemodialysis. Nephrol Dial Transplant. Published online November 11, 2026\. [Link](https://doi.org/10.1093/ndt/gfag261?ref=nephspace.com)
- Celebi E, et al. Burden of pruritus in older non-dialysis CKD stage 4-5 patients: 7-year follow-up of the EQUAL study. Nephrol Dial Transplant. Published online November 10, 2026\. [Link](https://doi.org/10.1093/ndt/gfag256?ref=nephspace.com)

**Listen anywhere:** [Apple Podcasts](https://podcasts.apple.com/podcast/nephspace/id6818364609?ref=nephspace.com) · [Spotify](https://open.spotify.com/show/13ehzk9U414PYpIZK3c4yv?ref=nephspace.com) · [other apps](https://nephspace.com/tag/episodes/#other-apps). **Discuss:** [NephSpace on LinkedIn](https://www.linkedin.com/company/nephspace?ref=nephspace.com).

*Physician-led, AI-assisted. Dr. Wael Hussein chooses the papers, reviews and edits every script, and approves every episode. AI (Claude, by Anthropic) writes the first draft from the full text of each paper, and a separate AI check compares every number with the papers; Dr. Hussein then reviews and edits the draft before the AI hosts (ElevenLabs) voice it. Everything is summarized in our own words. For education and information only, not medical advice. Please talk to your own physician or care team about your health. Clinicians: read the original before changing practice. See our [disclaimer](https://nephspace.com/disclaimer/). Views are the creator's own and not those of his employer. No sponsors.*